CALC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jun 2024 @ 04:00):

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs...

Stats
今日成交量	6 578.00
平均成交量	23 322.00
市值	61.05M
EPS	$0 ( 2024-05-10 )
下一个收益日期	( $-0.530 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.360
ATR14	$0.178 (3.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-17	Geffken Daniel E.	Buy	10 000	Warrant
2024-03-28	Guerard Frederic	Buy	10 000	Director Stock Option (Right to Buy)
2024-03-28	Bjerkholt Eric	Buy	10 000	Director Stock Option (Right to Buy)
2024-03-28	Shaw Allan	Buy	10 000	Director Stock Option (Right to Buy)
2024-03-28	Middleton Fred A	Buy	10 000	Director Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 99 transactions
Buy: 7 072 309 \| Sell: 0

CalciMedica, Inc. 相关性

10 最正相关
RFAIU	0.952
RILYT	0.924
NNAVW	0.915
ANL	0.914
RILYK	0.899
DECAU	0.898
MTTR	0.897
GTACW	0.895
RENE	0.892
ATMV	0.883

10 最负相关
OZEM	-1
INTJ	-0.919
NUVO	-0.911
ADNWW	-0.904
GBLMX	-0.901
SHOT	-0.896
RENB	-0.896
KYTX	-0.894
NTRP	-0.892
BNAI	-0.89

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CalciMedica, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-23.20

Financial Reports:

No articles found.

CalciMedica, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.